98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644878 | PMC |
http://dx.doi.org/10.3389/fimmu.2023.1323486 | DOI Listing |
J Thorac Oncol
July 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: TNM staging systems create prognostic categories by anatomic extent of disease. Whether therapeutically important molecular alterations in NSCLC augment the prognostic information of TNM staging is unclear. To study this, we analyzed molecular data from the ninth edition of the lung cancer staging system.
View Article and Find Full Text PDFBlood Neoplasia
November 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.
View Article and Find Full Text PDFFront Pain Res (Lausanne)
August 2025
Center for Veterinary Medicine, Food and Drug Administration, Rockville, MD, United States.
Annually, millions of humans and animals suffer from chronic and acute pain, creating welfare and quality of life concerns for both humans and animals who suffer this pain. In developing new therapeutic approaches, the challenge is to accurately measure this pain to ascertain the efficacy of novel therapeutics. Additionally, there is a need to develop new and effective analgesic options that may offer alternatives to using opioids that contribute to the opioid epidemic.
View Article and Find Full Text PDFFront Hum Neurosci
September 2025
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Primary progressive aphasia (PPA) is a neurological syndrome characterized by the gradual deterioration of language capabilities. Due to its neurodegenerative nature, PPA is marked by a continuous decline, necessitating ongoing and adaptive therapeutic interventions. Recent studies have demonstrated that behavioral therapies, particularly when combined with neuromodulation techniques such as transcranial direct current stimulation (tDCS), can improve treatment outcomes, including the long-term maintenance and generalization of therapeutic effects.
View Article and Find Full Text PDFNAR Cancer
September 2025
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.
Treatment of patients with platinum-resistant ovarian cancer is a major clinical challenge. We found that high expression of a meiotic protein, Synaptonemal Complex Protein 2 (SYCP2), is associated with platinum resistance and tyrosine kinase ABL1 inhibitor sensitivity in ovarian cancer. We demonstrate that tyrosine kinase ABL1 inhibitors inhibit cancer cell proliferation more efficiently in ovarian cancer cell lines with SYCP2 overexpression.
View Article and Find Full Text PDF